Sandra Elisa Adami Batista Gonçalves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra Elisa Adami Batista Gonçalves has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Z. Pereira
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Giovanna Braganholo Carpentieri
Departamento de Medicina, Divisão de Endocrinologia e Metabolismo, Universidade Federal de São Paulo, São Paulo, SP, Brasil,
2 shared publications - Thiago José Martins Gonçalves
Instituto Prevent Senior, Brazil
2 shared publications Andreia Guarnieri
Sancta Maggiore Hospital, Prevent Senior Private Health Operator São Paulo Brazil
1 shared publication- Andreza Alice Feitosa Ribeiro
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication Daniella Cabral de Freitas
Sancta Maggiore Hospital, Prevent Senior Private Health Operator São Paulo Brazil
1 shared publication
Latest Publications
- Open Access
- 7 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 442-449
Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder
Postprandial hypoglycemia (PPH) is a complex and multifactorial complication of bariatric surgery (BS). PPH may cause severe symptoms or be asymptomatic. The treatment of this condition requires dietary changes, but severe cases require drug therapy. The number of therapeutic options is limited and are often associated with adverse side effects. Different classes of drugs have been used and tested, but the resolution of PPH remains a challenge for physicians and patients. In this review, we gathered articles on PPH [...] ABSTRACT Postprandial hypoglycemia (PPH) is a complex and multifactorial complication of bariatric surgery (BS). PPH may cause severe symptoms or be asymptomatic. The treatment of this condition requires dietary changes, but severe cases require drug therapy. The number of therapeutic options is limited and are often associated with adverse side effects. Different classes of drugs have been used and tested, but the resolution of PPH remains a challenge for physicians and patients. In this review, we gathered articles on PPH
- 7 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 442-449
Open AccessHypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder
Postprandial hypoglycemia (PPH) is a complex and multifactorial complication of bariatric surgery (BS). PPH may cause severe symptoms or be asymptomatic. The treatment of this condition requires dietary changes, but severe cases require drug therapy. The number of therapeutic options is limited and are often associated with adverse side effects. Different classes of drugs have been used and tested, but the resolution of PPH remains a challenge for physicians and patients. In this review, we gathered articles on PPH [...] ABSTRACT Postprandial hypoglycemia (PPH) is a complex and multifactorial complication of bariatric surgery (BS). PPH may cause severe symptoms or be asymptomatic. The treatment of this condition requires dietary changes, but severe cases require drug therapy. The number of therapeutic options is limited and are often associated with adverse side effects. Different classes of drugs have been used and tested, but the resolution of PPH remains a challenge for physicians and patients. In this review, we gathered articles on PPH
- 8 June 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (8) , 2664-2671
SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery
Purpose Since SGLT2 inhibitors may reduce postprandial hyperglycemia, this study aimed to evaluated whether empagliflozin might be useful in the treatment of postprandial hypoglycemia (PPH) postbariatric surgery (BS). Patients and Methods Fourteen patients who underwent BS, nine without type 2 diabetes and five with diabetes before surgery and in remission after surgery, were included. Seven of them presented symptoms of PPH (hypoglycemic group; HG) and seven were asymptomatic (nonhypoglycemic group (NHG)). A meal tolerance test was performed before and after administration of a daily dose of empagliflozin (EMPA) 25 mg for 3 days. Plasma glucose and serum insulin levels were measured. Results In HG, compared with NHG, in the basal test, the area under the curve (AUC) of plasma glucose levels (AUCgly) was smaller (158.3 ± 25.3 vs 276.6 ± 79.2 mg h dL−1; p = 0.001) while the AUC of insulin levels (AUCins) did not differ, leading to a higher AUCins/AUCgly ratio (0.79 ± 0.46 vs 0.38 ± 0.20; p = 0.055) and a lower HOMA-IR (0.92 ± 0.22 vs 1.75 ± 0.77; p = 0.030). The HG after EMPA, but not the NHG, showed significant increases in glycemia leading to greater AUCgly (158.0 ± 25.3 to 197.2 ± 51.6 mg h dL−1; p = 0.043) without significant changes in AUCins. HOMA-IR increased only in the HG (0.92 ± 0.20 vs 1.61 ± 0.30; p = 0.025) and, when both groups were analyzed together, both before and post EMPA, a significant correlation was found between HOMA-IR and AUCgly values (r = 0.594; p = 0.002). Conclusion Our results suggest that empagliflozin increased glycemic levels in patients with PPH possibly through increases in hepatic glucose production. Graphical abstract
- 8 June 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (8) , 2664-2671
SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery
Purpose Since SGLT2 inhibitors may reduce postprandial hyperglycemia, this study aimed to evaluated whether empagliflozin might be useful in the treatment of postprandial hypoglycemia (PPH) postbariatric surgery (BS). Patients and Methods Fourteen patients who underwent BS, nine without type 2 diabetes and five with diabetes before surgery and in remission after surgery, were included. Seven of them presented symptoms of PPH (hypoglycemic group; HG) and seven were asymptomatic (nonhypoglycemic group (NHG)). A meal tolerance test was performed before and after administration of a daily dose of empagliflozin (EMPA) 25 mg for 3 days. Plasma glucose and serum insulin levels were measured. Results In HG, compared with NHG, in the basal test, the area under the curve (AUC) of plasma glucose levels (AUCgly) was smaller (158.3 ± 25.3 vs 276.6 ± 79.2 mg h dL−1; p = 0.001) while the AUC of insulin levels (AUCins) did not differ, leading to a higher AUCins/AUCgly ratio (0.79 ± 0.46 vs 0.38 ± 0.20; p = 0.055) and a lower HOMA-IR (0.92 ± 0.22 vs 1.75 ± 0.77; p = 0.030). The HG after EMPA, but not the NHG, showed significant increases in glycemia leading to greater AUCgly (158.0 ± 25.3 to 197.2 ± 51.6 mg h dL−1; p = 0.043) without significant changes in AUCins. HOMA-IR increased only in the HG (0.92 ± 0.20 vs 1.61 ± 0.30; p = 0.025) and, when both groups were analyzed together, both before and post EMPA, a significant correlation was found between HOMA-IR and AUCgly values (r = 0.594; p = 0.002). Conclusion Our results suggest that empagliflozin increased glycemic levels in patients with PPH possibly through increases in hepatic glucose production. Graphical abstract
- 15 January 2021
- Published by Wiley in Journal of Diabetes
- Vol. 13 (5) , 413-419
Association between thiamine deficiency and hyperlactatemia among critically ill patients with diabetes infected by SARS‐CoV‐2
Background: The present study aims to verify the association between diabetes and thiamine deficiency in critically ill patients infected by severe acute respiratory syndrome coronavirus 2.Methods: This is a descriptive cross‐sectional study, whose demographic, anthropometric, and laboratory data (arterial lactate, bicarbonate, and plasma thiamine) were obtained in the first hours of admission to the intensive care unit. Patients with diabetes were compared with individuals without diabetes, and the correlation was performed between thiamine and lactate levels. Thiamine levels P < .001). There was a strong negative correlation between thiamine and arterial lactate in patients with diabetes (r = −0.711, P < .001) and a moderate negative correlation in critically ill patients without diabetes (r = −0.489, P < .001).Conclusions: The prevalence of thiamine deficiency in critically ill patients due to coronavirus disease 2019 is higher in patients with diabetes. There is a negative correlation between thiamine and arterial lactate levels, which is higher in people with diabetes.
- 15 January 2021
- Published by Wiley in Journal of Diabetes
- Vol. 13 (5) , 413-419
Association between thiamine deficiency and hyperlactatemia among critically ill patients with diabetes infected by SARS‐CoV‐2
Background: The present study aims to verify the association between diabetes and thiamine deficiency in critically ill patients infected by severe acute respiratory syndrome coronavirus 2.Methods: This is a descriptive cross‐sectional study, whose demographic, anthropometric, and laboratory data (arterial lactate, bicarbonate, and plasma thiamine) were obtained in the first hours of admission to the intensive care unit. Patients with diabetes were compared with individuals without diabetes, and the correlation was performed between thiamine and lactate levels. Thiamine levels P < .001). There was a strong negative correlation between thiamine and arterial lactate in patients with diabetes (r = −0.711, P < .001) and a moderate negative correlation in critically ill patients without diabetes (r = −0.489, P < .001).Conclusions: The prevalence of thiamine deficiency in critically ill patients due to coronavirus disease 2019 is higher in patients with diabetes. There is a negative correlation between thiamine and arterial lactate levels, which is higher in people with diabetes.
- Open Access
- 1 November 2020
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (11) , e265-e270
Challenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host Disease
- 1 November 2020
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (11) , e265-e270
Open AccessChallenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host Disease
- Open Access
- 14 May 2019
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 17 (2) , eAE4340
Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly
The Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly was elaborated by nutritionists, nutrologists and hematologists physicians from 15 Brazilians reference centers in hematopoietic stem cell transplantation, in order to emphasize the importancy of nutritional status and the body composition during the treatment, as well as the main characteristics related to patient's nutritional assessment. Establishing the consensus, we intended to improve and standardize the nutritional therapy during the hematopoietic stem cell transplantation. The Consensus was approved by the Brazilian Society of Bone Marrow Transplantation.
- 14 May 2019
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 17 (2) , eAE4340
Open AccessBrazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly
The Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly was elaborated by nutritionists, nutrologists and hematologists physicians from 15 Brazilians reference centers in hematopoietic stem cell transplantation, in order to emphasize the importancy of nutritional status and the body composition during the treatment, as well as the main characteristics related to patient's nutritional assessment. Establishing the consensus, we intended to improve and standardize the nutritional therapy during the hematopoietic stem cell transplantation. The Consensus was approved by the Brazilian Society of Bone Marrow Transplantation.